Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
A Clinical Study of Hetrombopag Olamine Tablets for Thrombocytopenia Induced by Chemotherapy in Advanced Breast Cancer
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05394285
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
Camrelizumab Combined With Apatinib Mesylate
Not Applicable
Recruiting
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT05380986
- Locations
- 🇨🇳
Henan Tumor Hospital, Henan, China
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT05377658
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Pyrotinib Combined With Capecitabine in HER-2 Positive Advanced Breast Cancer and Brain Metastases (Post-PERMEATE)
- Conditions
- Breast Cancer
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05359120
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT05357417
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
Phase 1
Recruiting
- Conditions
- HR Positive HER2 Negative Advanced Breast Cancer
- Interventions
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 87
- Registration Number
- NCT05335473
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
Phase 2
Recruiting
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05328440
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer
Phase 2
- Conditions
- Advanced Gastric CarcinomaHER2-positive Gastric Cancer
- Interventions
- Drug: RC48+AK105+cisplatin
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05313906
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05299255
- Locations
- 🇨🇳
Henan Tumor Hospital, Zhengzhou, Henan, China
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 134
- Registration Number
- NCT05296577
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath